Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Forbes
Roche Holding’s (OTCMTS: RHHBY) Roche’s Revenues Roche’s Revenue Has Been On A Rise Over The Last Few Years Comparing Roche’s Sales Growth To Its Peers oche Has One of The Largest Oncology Drugs Portfolio, But It Is Expected To See A Decline Going Forward. However, some of the company’s big ticket older drugs, including Rituxan, Avastin, and rceptin are expected to see decline, as they face biosimilar competition. Ocrevus Has Been The Best Drug Launch Ever For Roche, Boosting Its Neuroscience Drugs Portfolio Other Therapeutic Drugs Could Also See Growth In The Near Term The jump in 2019 can largely be attributed to sales of $1.4 billion, as compared to $229 million sales in 2018. ’s peak sales are estimated to be over $5 billion, thereby boosting the segment revenues over the next few years. Among Other Segments, In-Vitro Diagnostics Could Continue To Grow At A Steady Pace, While Immunology, Ophthalmology, And Virology Drugs Could See A Decline See all Trefis Pr
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche and Zealand's Phase II obesity trial divides analyst opinion [Yahoo! Finance]Yahoo! Finance
- New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus [Yahoo! Finance]Yahoo! Finance
- New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of LupusBusiness Wire
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity [Yahoo! Finance]Yahoo! Finance